Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors

Khan, Tahsin M.; Garg, Malika; Warner, Richard R.P.; Uhr, Joshua H.; Divino, Celia M.

doi:10.1097/mpa.0000000000000572

Cited by 10 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated concentrations of pancreastatin correlate with a shorter progression-free survival (PFS) and the overall survival (OS) of patients with pancreatic and small bowel NETs, which makes it a potential prognostic biomarker [ 46 ]. It seems to be especially useful in metastatic disease and recent data suggests that it compares better to CgA in detecting the progression of midgut NETs [ 47 , 48 ].…”

Section: Discussionmentioning

confidence: 99%

Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future

Komarnicki

Musiałkiewicz

Stańska

et al. 2022

JCM

View full text Add to dashboard Cite

Neuroendocrine tumors are a heterogeneous group of neoplasms originating from the diffuse endocrine system. Depending on primary location and hormonal status, they range in terms of clinical presentation, prognosis and treatment. Functional tumors often develop symptoms indicating an excess of hormones produced by the neoplasm (exempli gratia insulinoma, glucagonoma and VIPoma) and can be diagnosed using monoanalytes. For non-functional tumors (inactive or producing insignificant amounts of hormones), universal biomarkers have not been established. The matter remains an important unmet need in the field of neuroendocrine tumors. Substances researched over the years, such as chromogranin A and neuron-specific enolase, lack the desired sensitivity and specificity. In recent years, the potential use of Circulating Tumor Cells or multianalytes such as a circulating microRNA and NETest have been widely discussed. They offer superior diagnostic parameters in comparison to traditional biomarkers and depict disease status in a more comprehensive way. Despite a lot of promise, no international standards have yet been developed regarding their routine use and clinical application. In this literature review, we describe the analytes used over the years and cover novel biomarkers that could find a use in the future. We discuss their pros and cons while showcasing recent advances in the field of neuroendocrine tumor biomarkers.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future

Komarnicki

Musiałkiewicz

Stańska

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Pancreastatin is a breakdown product of CgA. Compared to CgA, and similar to CgB, pancreastatin can be more specific among patients receiving PPI, while increased levels have been associated with SI-NETs liver metastases [35]. A recent retrospective study by Tran et al, comprising of 218 SI-NET patients, showed that pancreastatin may also be superior to CgA in detecting SI-NET disease progression with an overall accuracy of 78.9% [36].…”

Section: Pancreastatinmentioning

confidence: 99%

Biomarkers in Small Intestine NETs and Carcinoid Heart Disease: A Comprehensive Review

Kalligeros

Diamantopoulos

Toumpanakis

2021

Biology

View full text Add to dashboard Cite

Biomarkers remain a valuable tool for the diagnosis and management of Neuroendocrine tumors (NETs). Traditional monoanalyte biomarkers such as Chromogranin A (CgA) and 5-Hydrocyondoleacetic acid (5-HIAA) have been widely used for many years as diagnostic, predictive and prognostic biomarkers in the field of NETs. However, the clinical utility of these molecules often has limitations, mainly inherent to the heterogeneity of NETs and the fact that these tumors can often be non-secretory. The development of new molecular multianalyte biomarkers, especially the mRNA transcript based “NETest”, has rapidly evolve the field and gives the ability for a “liquid biopsy” which can reliably assess disease status in real time. In this review we discuss the use of established and novel biomarkers in the diagnosis and management of small intestine NETs and carcinoid heart disease.

show abstract